Skip to main content
Fig. 2 | European Journal of Medical Research

Fig. 2

From: The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials

Fig. 2

Meta-analysis of the clinical outcomes under anti-amyloid-β monoclonal antibodies in patients with AD. Forest plot showed the comparisons of mean changes between drugs and placebo on several tests: Changes in CDR-SB (a), Changes in ADCS-ADL-MCI (b), Changes in ADCOMS (c), and Changes in ADAS-Cog (d)

Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us